Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen

Journal of the National Cancer Institute

Volumn 85, Issue 17, 1993, Pages 1398-1406

  Rutqvist, Lars E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEART DISEASES; HUMAN; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TAMOXIFEN; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027325734     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.17.1398     Document Type: Article

References (32)

1. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
2. Rutqvist LE, Cedermark B, Glas U, et al: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299-1306, 1991.
3. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-120, 1989.
4. Oliver MF, Boyd GS: Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels. Lancet 2:690-694, 1959.
5. Parrish HM, Carr CA, Hall DG, et al: Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 99:155-162, 1967.
6. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse’s Health Study. N Engl J Med 325:756-762, 1991.
7. Fornander T, Rutqvist LE, Wilking N, et al: Estrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer. In press.
8. ROssner S, Walllgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339-346, 1984.
9. Rutqvist LE, Cedermark B, Glas U, et al: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10:255-266, 1987.
10. Rutqvist LE, Cedermark B, Glas U, et al: Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 66:89-96, 1990.
11. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 9:1740-1748, 1991.
12. Fornander T: Long-term adjuvant tamoxifen in postmenopausal breast cancer. Adverse effects among patients included in a randomized clinical trial (Thesis). Karolinska Institute, Stockholm, 1990.
13. World Health Organization: International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 8th revision. Geneva: WHO, 1969.
14. Cutler S, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chron Dis 8:699-710, 1958.
15. Haybittle JL: The reporting of non-significant results in clinical trials. In Clinical Trials in “Early” Breast Cancer. Lecture Notes in Medical Informatics (Scheurlen HR, Weckesser G, Arbruster I, eds), vol 4. Berlin-Heidelberg. Springer-Verlag, 1979, pp 28-29.
16. Ahlbom A: Acute myocardial infarction in Stockholm-A medical information system as an epidemiological tool. Int J Epidemiol 7:271-276, 1978.
17. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435-437, 1991.
18. Gangar KF, Vyas S, Whitehead M, et al: Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 338:839-842, 1991.
19. de Ziegler D, Bessis R, Frydman R: Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil Steril 55:775-779, 1991.
20. Stumpf WE: Steroid hormones and the cardiovascular system: direct actions of estradiol, progesterone, testosterone, gluco-and mineralcor-ticoids, and soltriol-vitamin D-on central nervous regulatory and peripheral tissues. Experientia 46:13-25, 1990.
21. Fisher B, Brown A, Wolmark N, et al: Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649-654, 1987.
22. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013-1017, 1991.
23. Ryden S, Ferno M, MOller T, et al: Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Trial. Acta Oncologica. In press.
24. Boccardo F, Bruzzi P, Rubagotti A, et al: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281-285, 1981.
25. De Muylder X, Neven P, De Somer M, et al: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127-130, 1991.
26. Gottardis MM, Robinson SP, Jordan VC: Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30:311-314, 1988.
27. Fentiman IS, Powles TJ: Tamoxifen and benign breast problems. Lancet 2:1070-1072, 1987.
28. Enck RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53:2607-2609, 1984.
29. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517-4519, 1987.
30. Auger MJ, Mackie MJ: Effects of tamoxifen on blood coagulation. Cancer 61:1316-1319, 1988.
31. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991.
32. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989.